Are Investors Undervaluing Sutro Biopharma, Inc. (NASDAQ:STRO) By 46%?
JMP Securities Remains a Buy on Sutro Biopharma (STRO)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Zynex (ZYXI), Sutro Biopharma (STRO) and Amryt Pharma (AMYT)
Sutro Biopharma (NASDAQ:STRO) PT Raised to $25.00 at Truist Financial
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price upped by stock analysts at Truist Financial from $21.00 to $25.00 in a research note issued to investors on Friday, The Fly reports. T
Sutro Biopharma Price Target Raised to $25.00/Share From $21.00 by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Is Maintained at Buy by Truist Securities
Sutro Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/13/2023 225.95% Truist Securities $21 → $25 Maintains Buy 01/10/2023 134.68% Piper Sandler $16 → $18 Ma
Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25
Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $21 to $25.
Sutro Biopharma (NASDAQ:STRO) Price Target Raised to $18.00
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price boosted by Piper Sandler from $16.00 to $18.00 in a report published on Tuesday morning, The Fly reports. They currently have an overwe
Sutro Biopharma (NASDAQ:STRO) Given New $18.00 Price Target at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price lifted by Piper Sandler from $16.00 to $18.00 in a research report released on Tuesday morning, The Fly reports. They currently have an
Loading...
No Stock Yet